Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oric Pharmaceuticals ( (ORIC) ) has issued an announcement.
ORIC Pharmaceuticals plans to present an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting its progress in advancing two lead programs, ORIC-114 and ORIC-944, towards pivotal studies. With a strong financial position, the company is well-positioned to continue its development pipeline, targeting new investigational new drug candidates and anticipating significant data milestones in the upcoming years, which could strengthen its industry positioning and impact stakeholders by addressing unmet needs in cancer treatment.
More about Oric Pharmaceuticals
ORIC Pharmaceuticals operates in the biotechnology industry, primarily focusing on the development and commercialization of oncology therapies. The company aims to overcome resistance in cancer treatments with a robust pipeline built from both internal research and external business development.
YTD Price Performance: -3.63%
Average Trading Volume: 436,162
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $561.7M
For a thorough assessment of ORIC stock, go to TipRanks’ Stock Analysis page.
